GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioStem Technologies Inc (OTCPK:BSEM) » Definitions » EV-to-Revenue

BioStem Technologies (BioStem Technologies) EV-to-Revenue : 22.29 (As of May. 05, 2024)


View and export this data going back to 2008. Start your Free Trial

What is BioStem Technologies EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, BioStem Technologies's enterprise value is $110.72 Mil. BioStem Technologies's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $4.97 Mil. Therefore, BioStem Technologies's EV-to-Revenue for today is 22.29.

The historical rank and industry rank for BioStem Technologies's EV-to-Revenue or its related term are showing as below:

BSEM' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.87   Med: 37.49   Max: 1027.18
Current: 22.29

During the past 13 years, the highest EV-to-Revenue of BioStem Technologies was 1027.18. The lowest was 2.87. And the median was 37.49.

BSEM's EV-to-Revenue is ranked worse than
70.27% of 1036 companies
in the Biotechnology industry
Industry Median: 7.98 vs BSEM: 22.29

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-05), BioStem Technologies's stock price is $8.00. BioStem Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.37. Therefore, BioStem Technologies's PS Ratio for today is 21.51.


BioStem Technologies EV-to-Revenue Historical Data

The historical data trend for BioStem Technologies's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioStem Technologies EV-to-Revenue Chart

BioStem Technologies Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.40 10.74 7.57 3.87 5.94

BioStem Technologies Quarterly Data
Sep15 Dec15 Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.19 11.77 5.94 18.60 8.09

Competitive Comparison of BioStem Technologies's EV-to-Revenue

For the Biotechnology subindustry, BioStem Technologies's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioStem Technologies's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's EV-to-Revenue falls into.



BioStem Technologies EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

BioStem Technologies's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=110.715/4.968
=22.29

BioStem Technologies's current Enterprise Value is $110.72 Mil.
BioStem Technologies's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioStem Technologies  (OTCPK:BSEM) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

BioStem Technologies's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=8.00/0.372
=21.51

BioStem Technologies's share price for today is $8.00.
BioStem Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.37.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioStem Technologies EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioStem Technologies's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BioStem Technologies (BioStem Technologies) Business Description

Traded in Other Exchanges
N/A
Address
2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include RHEO, AEON, OROPRO, VENDAJE, VENDAJE AC, and VENDAJE OPTIC.